From owner-doc-jp@jp.FreeBSD.org Tue Feb 26 12:40:27 2002
Received: (from daemon@localhost)
	by castle.jp.FreeBSD.org (8.11.6+3.4W/8.11.3) id g1Q3eRK54531;
	Tue, 26 Feb 2002 12:40:27 +0900 (JST)
	(envelope-from owner-doc-jp@jp.FreeBSD.org)
Received: from mail ([142.179.212.34])
	by castle.jp.FreeBSD.org (8.11.6+3.4W/8.11.3) with ESMTP/inet id g1Q3eOW54525
	for <doc-jp@jp.freebsd.org>; Tue, 26 Feb 2002 12:40:24 +0900 (JST)
	(envelope-from wsch8000@eudoramail.com)
Received: from mx1.eudoramail.com (unverified [204.32.146.147]) by mail
 (Rockliffe SMTPRA 4.5.6) with ESMTP id <B0000006461@mail>;
 Mon, 25 Feb 2002 20:38:29 -0700
Message-ID: <00007e156a83$00003627$000001e8@mx1.eudoramail.com>
To: <Mainly.Millionaires>
From: wsch8000@eudoramail.com
Date: Mon, 25 Feb 2002 21:40:07 -1800
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Reply-To: wsch8000@eudoramail.com
Precedence: list
X-Distribute: distribute version 2.1 (Alpha) patchlevel 24e+011218
X-Sequence: doc-jp 8771
Subject: [doc-jp 8771] WSCH : A Revolutionary Acne Treatment and More  Z
Errors-To: owner-doc-jp@jp.FreeBSD.org
Sender: owner-doc-jp@jp.FreeBSD.org
X-Originator: wsch8000@eudoramail.com

<html><head><meta http-equiv=3DContent-Type content=3D"text/html; charset=3D=
windows-1252"><title>SPECIAL ALERT</title></head><body><table cellSpacing=3D=
0 cellPadding=3D0 width=3D604 bgColor=3D#000000 border=3D0><tr><td width=3D=
604><div align=3Dleft><img border=3D0 src=3Dhttp://us.f1.yahoofs.com/users=
/1e1000e9/bc/friends/__hr_HEADER4.jpg?bc0nix8A5efRG04T></div></td></tr></t=
able><table cellSpacing=3D0 cellPadding=3D2 width=3D602 border=3D0 height=3D=
2863><tr><td vAlign=3Dtop align=3Dleft bgColor=3D#000000 height=3D2859><ta=
ble cellSpacing=3D0 cellPadding=3D3 width=3D561 bgColor=3D#ffffff border=3D=
0 height=3D2875><tr><td bgColor=3D#000000 height=3D19><table cellSpacing=3D=
0 cellPadding=3D0 width=3D591 border=3D0><tr><td vAlign=3Dcenter align=3Dl=
eft width=3D591><p align=3Dcenter><b><font face=3D"Times New Roman, Times,=
 serif" color=3D#FFFFDD>Special Alert </font><font face=3D"Times New Roman=
, Times, serif" size=3D2 color=3D#FFFFDD>:</font><font face=3D"Times New R=
oman, Times, serif" size=3D2 color=3D#FFFFE1> </font><font face=3D"Times N=
ew Roman, Times, serif" color=3D#FFFFFF>&nbsp;WASATCH&nbsp; PHARMACEUTICAL=
S </font><font face=3D"Times New Roman, Times, serif" size=3D2 color=3D#FF=
FFFF>&nbsp;</font><font face=3D"Times New Roman, Times, serif" color=3D#FF=
FFDD>(OTCBB: WSCH)</font></b></td></tr></table></td></tr><tr><td bgColor=3D=
#ffffff height=3D6><img height=3D4 src=3Dhttp://www.businessworldwide.net/=
sik/spacer.gif width=3D592 NOSEND=3D1></td></tr><tr><td vAlign=3Dtop align=
=3Dleft height=3D816><div align=3Dright><table cellSpacing=3D0 cellPadding=
=3D3 width=3D565 border=3D0 style=3D"border-collapse: collapse" bordercolo=
r=3D#111111 height=3D1 align=3Dright><tr><td vAlign=3Dtop align=3Dleft wid=
th=3D5 rowspan=3D6 height=3D638><table cellSpacing=3D0 cellPadding=3D3 wid=
th=3D288 border=3D0 height=3D872><tr bgColor=3D#099DF7><td height=3D1 widt=
h=3D25><p align=3Dleft><img border=3D0 src=3Dhttp://us.f1.yahoofs.com/user=
s/15e54a78/bc/bosko+family/__tn_arrow25.gif?bcKX9t8ANyXtRQyZ><font face=3D=
Batang style=3D"font-size: 11pt"></font></td><td height=3D1 width=3D251><p=
 align=3Dleft><span style=3D"font-weight: 700"><font face=3D"Times New Rom=
an" style=3D"font-size: 13pt">TOP&nbsp;4 REASONS TO BUY WSCH</font></span>=
</td></tr><tr><td colSpan=3D2 height=3D4 width=3D282><img height=3D2 src=3D=
http://www.businessworldwide.net/sik/spacer.gif width=3D280 NOSEND=3D1></t=
d></tr><tr><td vAlign=3Dtop align=3Dright width=3D25 height=3D64><font fac=
e=3D"Verdana, Geneva, Helvetica, Arial, sans-serif" size=3D2><b>1.</b></fo=
nt></td><td vAlign=3Dtop align=3Dleft width=3D251 height=3D64><font face=3D=
"Times New Roman">The products and medical therapies developed by WSCH rep=
resent possibly the <b>most important breakthrough</b> in the field of Der=
matology in the last fifty years.</font></td></tr><tr><td vAlign=3Dtop ali=
gn=3Dright width=3D25 height=3D48><b><font face=3D"Verdana, Geneva, Helvet=
ica, Arial, sans-serif" size=3D2>2.</font></b></td><td vAlign=3Dtop align=3D=
left width=3D251 height=3D48><font face=3D"Times New Roman">WSCH anticipat=
es <b>FDA approval</b> on seven over-the-counter products within the next =
year, which will provide significant revenue in the retail drug market.</f=
ont></td></tr><tr><td vAlign=3Dtop align=3Dright width=3D25 height=3D80><b=
><font face=3D"Verdana, Geneva, Helvetica, Arial, sans-serif" size=3D2>3.<=
/font></b></td><td vAlign=3Dtop align=3Dleft width=3D251 height=3D80><font=
 face=3D"Times New Roman">WSCH has experienced a <b>success rate of 90%</b=
> during clinical studies, completely eliminating skin disease from 90% of=
 all patients treated.</font></td></tr><tr><td vAlign=3Dtop align=3Dright =
width=3D25 height=3D80><b><font face=3D"Verdana, Geneva, Helvetica, Arial,=
 sans-serif" size=3D2>4.</font></b></td><td vAlign=3Dtop align=3Dleft widt=
h=3D251 height=3D80><font face=3D"Times New Roman">By year five, WSCH plan=
s to have annualized revenue over <b>$525 million</b> and over <b>$125 mil=
lion in EBIT</b>.&nbsp; This does not take into account income from OTC pr=
oducts which will be substantial.</font><p>&nbsp;</td></tr><tr bgColor=3D#=
099DF7><td height=3D1 width=3D25><p align=3Dleft><img border=3D0 src=3Dhtt=
p://us.f1.yahoofs.com/users/15e54a78/bc/bosko+family/__tn_arrow25.gif?bcKX=
9t8ANyXtRQyZ><font face=3DBatang style=3D"font-size: 11pt"></font></td><td=
 height=3D1 width=3D251><p align=3Dleft><span style=3D"font-weight: 700"><=
font face=3D"Times New Roman" style=3D"font-size: 13pt">&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROJECTIONS, =
OBJECTIVES AND STATISTICS</font></span></td></tr><tr><td vAlign=3Dtop alig=
n=3Dleft width=3D276 height=3D548 colspan=3D2><p class=3DMsoNormal>&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
; Over a five year period, AISC (WSCH's subsidiary) plans to establish <b>=
350 clinics in over 100 major population areas</b>.&nbsp;The company plans=
 to hire over 150 medical doctors for these clinics, train over 1,000 medi=
cal assistants and treat over <b>2,000,000 patients</b>. Also by year five=
, WSCH plans to have annualized over <u>$525 million in revenue and over $=
125 million in EBIT</u>. This does not take into account income from OTC p=
roducts which will be substantial.</p><p class=3DMsoNormal><span style=3D"=
font-size: 12.0pt; font-family: Times New Roman">As of 1991, there were ap=
proximately <b>14 million </b>chronic acne and eczema patients annually in=
 the United States,&nbsp;with the highest percentage between 18 to 44 year=
s of&nbsp;age. The actual number of patients with any type of acne&nbsp;Is=
 significantly higher.&nbsp;<b>Seven billion dollars is spent&nbsp;annuall=
y </b>on dermatological pharmaceutical products for&nbsp;these disorders.<=
/span></p><p class=3DMsoNormal><span style=3D"font-size: 12.0pt; font-fami=
ly: Times New Roman">In 1994, the teen population reached 25 million. Duri=
ng&nbsp;the next decade, it will grow at <b>nearly twice the rate of&nbsp;=
the overall population</b> (according to U.S. Census Bureau&nbsp;projectio=
ns).&nbsp;Acne patients are primarily teenagers,&nbsp;whereas eczema patie=
nts range from infants to the&nbsp;elderly</span>.</td></tr></table></td><=
td vAlign=3Dtop align=3Dleft width=3D277 rowspan=3D6 height=3D1></td><td v=
Align=3Dtop align=3Dleft width=3D239 height=3D1><table cellSpacing=3D0 cel=
lPadding=3D4 border=3D0 width=3D250><tr><td vAlign=3Dcenter align=3Dmiddle=
 bgColor=3D#099DF7 height=3D118 width=3D282><table cellSpacing=3D0 cellPad=
ding=3D0 width=3D260 bgColor=3D#ffffff border=3D0><tr><td vAlign=3Dtop ali=
gn=3Dleft height=3D101><table cellSpacing=3D0 cellPadding=3D4 width=3D235 =
border=3D0 align=3Dleft><tr><td width=3D123><b><font face=3DArial color=3D=
#339933 style=3D"font-size: 9pt">&nbsp;&nbsp;&nbsp; </font><font face=3DAr=
ial color=3D#339933 size=3D2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SYMBOL:</font>=
</b></td><td width=3D96><b><font face=3DArial size=3D2>&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp; WSCH</font></b></td></tr><tr><td width=3D123><b><f=
ont face=3DArial style=3D"font-size: 9pt" color=3D#339933>&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp; CURRENT PRICE:</font></b></td><td width=3D96><font fa=
ce=3D"Bookman Old Style" size=3D2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </f=
ont><font face=3D"Times New Roman"><b>$0.0</b></font><b><font face=3D"Time=
s New Roman">59</font></b></td></tr><tr><td width=3D123><font face=3DArial=
 color=3D#339933><b><font style=3D"font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp; 52 WEEK HIGH:</font></b></font></td><td width=3D96><font fac=
e=3D"Bookman Old Style" size=3D2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </fo=
nt><b><font face=3D"Times New Roman">$27.50</font></b></td></tr><tr><td wi=
dth=3D123><b><font face=3DArial style=3D"font-size: 9pt" color=3D#339933>&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52 WEEK LOW:</font></b></td><td width=3D=
96><font face=3D"Bookman Old Style" size=3D2>&nbsp;&nbsp;&nbsp;&nbsp; </fo=
nt><font face=3D"Times New Roman"><b>&nbsp; <font color=3D#339933>$0.0</fo=
nt></b></font><b><font face=3D"Times New Roman" color=3D#339933>56</font><=
/b></td></tr></table></td></tr></table></td></tr><tr><td vAlign=3Dcenter a=
lign=3Dleft width=3D282><img height=3D2 src=3Dhttp://www.businessworldwide=
.net/sik/spacer.gif width=3D280 NOSEND=3D1></td></tr></table><table cellSp=
acing=3D0 cellPadding=3D3 width=3D288 border=3D0 height=3D1><tr bgColor=3D=
099df7><td height=3D1 width=3D1><p align=3Dleft><img border=3D0 src=3Dhttp=
://us.f1.yahoofs.com/users/15e54a78/bc/bosko+family/__tn_arrow25.gif?bcKX9=
t8ANyXtRQyZ><font face=3DBatang style=3D"font-size: 11pt"></font></td><td =
height=3D1 width=3D500><p align=3Dleft><span style=3D"font-weight: 700"><f=
ont face=3D"Times New Roman" style=3D"font-size: 13pt">COMPANY BACKGROUND<=
/font></span></td></tr></table></td></tr><tr><td vAlign=3Dtop align=3Dleft=
 width=3D284 height=3D1><p class=3DMsoNormal>Wasatch Pharmaceutical, Inc. =
is a fourteen year old company with a record of outstanding achievements i=
n the field of Dermatology. Dermatology.&nbsp;Under the name of its subsid=
iary, American Institute of Skin Care <b>(AISC)</b>, Wasatch has operated =
two prototype clinics for the last five years where the products and medic=
al therapies have been tested and proven on hundreds of patients. The Comp=
any's activities have been centered on research in the area of <b>serious =
skin diseases</b>.&nbsp;<font face=3D"Times New Roman">A concurrent discov=
ery and benefit is WSCH's dramatic success in the area of skin rejuvenatio=
n.</font></td></tr><tr><td vAlign=3Dtop align=3Dleft width=3D284 height=3D=
11><font face=3D"Times New Roman">Seeing the high growth potential from ma=
jor funding, WSCH elected to <b>become a public company</b> less than two =
years ago.</font><p><font face=3D"Times New Roman">Wasatch's major success=
es in the area of skin diseases include:</font></td></tr><tr><td vAlign=3D=
top align=3Dleft width=3D284 height=3D14><font face=3D"Times New Roman"><b=
>Cystic Acne, Eczema, Seborrhea, Contact Dermatitis, Molluscum, Folliculit=
is, Acne Rosacea and less prevalent skin diseases.</b></font></td></tr><tr=
><td vAlign=3Dtop align=3Dleft width=3D284 height=3D19><font face=3D"Times=
 New Roman">Interestingly, these skin disorders account for more than <b>7=
0% of all business</b> in the field of dermatology for which there are ver=
y few (if any) safe, effective therapies like those developed by <b>Wasatc=
h.</b></font></td></tr><tr><td vAlign=3Dtop align=3Dleft width=3D284 heigh=
t=3D29><font face=3D"Times New Roman">Because the therapies developed by W=
asatch <b>dominate</b> this area of medicine, WSCH has elected to market i=
ts products via company-owned clinics throughout the United States.&nbsp;T=
his decision has resulted in the establishment of <b>two research clinics<=
/b> in Utah for the purpose of implementing procedures within the clinics =
pursuant to testing and confirming the results that were achieved in past =
clinical trials. </font>Due to its <b>success rate of 90% on hundreds of p=
atients over a five year period</b>, WSCH's clinics are now on line with i=
nsurance providers independent of HMOs. Efforts to establish Preferred Pro=
vidership status with HMOs are presently being pursued.</td></tr></table><=
/div></td></tr><tr><td height=3D23><table cellSpacing=3D0 cellPadding=3D2 =
width=3D592 bgColor=3D#006633 border=3D0><tr><td align=3Dmiddle width=3D54=
5 bgColor=3D#099df7><b><font face=3D"Times New Roman, Times, serif">THIS J=
UST IN : WSCH BREAKING NEWS</font></b></td></tr></table></td></tr><tr><td =
vAlign=3Dtop align=3Dleft height=3D1981>&nbsp;<table cellSpacing=3D0 cellP=
adding=3D4 width=3D587 border=3D0 height=3D1845><tr><td vAlign=3Dtop align=
=3Dleft height=3D737><h2><span style=3D"font-size: 13pt">Wasatch Pharmaceu=
tical Inc. Announces a New Physician Marketing Campaign and Listing On Ger=
man Stock Exchanges</span></h2> <h2><span style=3D"font-weight: 400"><font=
 face=3D"Times New Roman" size=3D3>MURRAY, Utah--(BUSINESS WIRE)--Nov. 27,=
 2001--Wasatch Pharmaceutical Inc. (OTCBB:<a href=3Dhttp://finance.yahoo.c=
om/q?s=3Dwsch.ob&d=3Dt>WSCH</a> - <a href=3Dhttp://biz.yahoo.com/n/w/wsch.=
ob.html>news</a>) CEO Gary Heesch announced today a marketing campaign dir=
ected to physicians. A direct link has been established on a physician rec=
ruiting Web site making available therapies for the treatment of cystic ac=
ne, acne, folliculitis and skin rejuvenation. Physicians will find the ben=
efits of these treatment therapies by logging on to the <b>&quot;X Acne&qu=
ot; link at the Physician Search website</b>. This physician search Web si=
te typically receives over <b>200,000 hits per month</b>. Mr. Heesch remin=
ded, &quot;Our treatment therapy products are also available via the AISC =
Online Store.&quot;</font></span></h2><p><font face=3D"Times New Roman">Th=
ese skin treatment products come in kit form providing a 90-day supply to =
patients for the full treatment program. Included in the kit is an instruc=
tional video on the treatment therapy allowing the patient to use these pr=
oducts in their home. The therapies, when used as instructed, achieve a <b=
>success rate of eradication in excess of 90% with no side effects of any =
consequence</b>. Previously, these therapies and associated products were =
only available through the two prototype clinics in Utah. The availability=
 of these products will open the way for family practitioners, pediatricia=
ns, internists and other primary care physicians to retain their patients =
under their care during the treatment of these common skin disorders. <b>T=
he benefit to insurance providers is the potential to save millions of dol=
lars in reimbursement costs by freeing the physician and the patient from =
ongoing treatment.</b></font></p><p><font face=3D"Times New Roman">In the =
coming year, <u>six additional therapies will be made available</u> for a =
broad range of skin disorders that are badly in need of successful therapi=
es.</font></p><p><font face=3D"Times New Roman">Gary Heesch also announced=
 the listing of Wasatch Pharmaceutical stock on the <b>Frankfurt and Berli=
n Exchanges in Germany</b>. Active trading on these exchanges will take pl=
ace upon the completion of a research report in Germany. Said Mr. Heesch, =
&quot;We feel this is a significant event as Wasatch will gain <b>wider ex=
posure</b> as a leader in dermatology and will put <u>buying</u> <u>pressu=
re on its stock to <b>reflect the true value</b> </u>of a company that has=
 committed years of research and development of products that allow people=
 with serious skin disorders to live normal and more productive lives.&quo=
t;</font></p><p><font face=3DArial size=3D1><i>There may be forward-lookin=
g statements in this release. Investors are cautioned that such forward-lo=
oking statements involve risks and uncertainties, including, without limit=
ation, continued acceptance of the Company's products, increased levels of=
 competition, new products introduced by competitors, changes in the rates=
 of subscriber acquisition and retention, and other risks detailed from ti=
me to time in the Company's periodic reports filed with the Securities and=
 Exchange Commission.</i></font><font face=3D"Times New Roman"></font></td=
></tr><tr><td vAlign=3Dtop align=3Dleft height=3D10 bgcolor=3D#099DF7><p a=
lign=3Dcenter><b>A LOOK AT THE COMPETITION</b></td></tr><tr><td vAlign=3Dt=
op align=3Dleft height=3D64><span style=3D"font-size: 12.0pt; font-family:=
 Times New Roman">Dermatologists are the primary competitors of WSCH's cli=
nics. Dermatologists specialize in the treatment of skin disorders and pre=
scribe medications to treat the disorder. However, competing products addr=
ess the <b>symptoms</b> of acne and eczema, <b>not the cause.&nbsp;</b></s=
pan><p><span style=3D"font-size: 12.0pt; font-family: Times New Roman">The=
 competition's skin care treatments include prescription medications (oral=
 and external use drugs prescribed by dermatologists and other doctors) an=
d over-the-counter products.</span></p><p class=3DMsoNormal><b>Several com=
mon prescription medications include:&nbsp;</b></p><p class=3DMsoNormal>1)=
 E-Mycin for oral and topical use, 2) Cleocin for oral and topical use, 3)=
 Tetracycline for oral and topical use, and 4) Accutane for oral use only.=
</p><p class=3DMsoNormal><b>Over-the-counter acne medications include:&nbs=
p;</b><br> 1) Clearasil and Oxy creams, 2) generic brand creams, 3) medica=
ted pads, and 4) medicated soaps.</p><p class=3DMsoNormal><i><u>Many of th=
e competition's oral medications have serious side effects.</u></i></p><p =
class=3DMsoNormal><span style=3D"font-size: 12.0pt; font-family: Times New=
 Roman">Costs for competing treatments range from $2.50 for medicated soap=
s to $200 for Accutane oral medication prescription. Treatments are on-goi=
ng.&nbsp;Over time a person can spend an <b>unlimited amount of money</b> =
on such treatments.&nbsp;An example would be someone who spent $1,500 for =
a 22 week program of Accutane which includes blood testing.&nbsp;Another e=
xample would be someone who has had acne for many years and has spent in e=
xcess of $34,000.</span></p><p class=3DMsoNormal>At this time there is <b>=
no known competitor </b>who treats the causes of these skin disorders and =
no competitor can claim a <b>success rate</b> equal to that of Wasatch's t=
reatments.</td></tr><tr><td vAlign=3Dtop align=3Dleft width=3D587 height=3D=
19 bgcolor=3D#099DF7><p align=3Dcenter><b>A FINAL WORD ABOUT WSCH</b></td>=
</tr><tr><td vAlign=3Dtop align=3Dleft height=3D112><p class=3DMsoNormal>W=
ith a proven success rate of 90% in a field that affects so many of our li=
ves, Wasatch has clearly positioned itself in a market <b>hungry and despe=
rate</b> for successful products and treatment.&nbsp;WSCH has recently exp=
anded its marketing presence (as seen in the above press release) and will=
 continue to aggressively broaden awareness over the near term. The listin=
g of <b>WSCH</b> on the German stock exchange is another sign of the compa=
ny's credibility and ambitious plans to establish itself as a <b>major glo=
bal player</b> in the field of dermatology.</p><b><span style=3D"FONT-SIZE=
: 10pt"><font face=3DVerdana color=3D#000000>&nbsp;</font></span></b>WSCH =
has taken on a completely different approach.&nbsp;By addressing the cause=
s of skin disorders rather than the symptoms, WSCH will help to successful=
ly eliminate skin disease altogether. Given the following:<p class=3DMsoNo=
rmal>1. Successful 14-year history and plans for expansion<br> 2. Impressi=
ve revenue projections ($525 million+ annualized&nbsp;by year 5 and $125 m=
illion in EBIT)<br> 3. Virtually unmatched success rate of 90%...</p><p cl=
ass=3DMsoNormal><span style=3D"font-size: 12.0pt; font-family: Times New R=
oman">...<b>and so much more, WSCH will certainly be watched by savvy inve=
stors for some time to come.</b></span></td></tr><tr><td vAlign=3Dtop alig=
n=3Dleft width=3D587 height=3D19><p align=3Dcenter><b><font face=3DVerdana=
 color=3D#099DF7 size=3D2>To be removed from future mailings, please reply=
 to this email with &quot;Remove&quot; in the subject line</font></b></td>=
</tr><tr><td vAlign=3Dtop align=3Dleft height=3D371><b><font face=3DVerdan=
a color=3D#efefef size=3D1><br> </font></b><font face=3D"Times New Roman" =
style=3D"font-size: 9pt">DISCLAIMER:&nbsp;<br> Information within this ema=
il contains &quot;forward looking statements&quot; within the meaning of S=
ection 27A of the Securities Act of 1933 and Section 21B of the Securities=
 Exchange Act of 1934. Any statements that express or involve discussions =
with respect to predictions, expectations, beliefs, plans, projections, ob=
jectives, goals, assumptions or future events or performance are not state=
ments of historical fact and may be &quot;forward looking statements.&quot=
;<br> <br> Forward looking statements are based on expectations, estimates=
 and projections at the time the statements are made that involve a number=
 of&nbsp;risks and uncertainties which could cause actual results or event=
s to differ materially from those presently anticipated. Forward looking s=
tatements in this action may be identified through the use of words such a=
s &quot;projects&quot;, &quot;foresee&quot;, &quot;expects&quot;, &quot;wi=
ll,&quot;&nbsp; &quot;anticipates,&quot; &quot;estimates,&quot; &quot;beli=
eves,&quot; &quot;understands&quot; or that by statements indicating certa=
in actions &quot;may,&quot; &quot;could,&quot; or &quot;might&quot; occur.=
&nbsp; All information provided within this email pertaining to investing,=
 stocks, securities must be understood as information provided and not inv=
estment advice. Emerging Growth Stock Alert advises all readers and subscr=
ibers to seek&nbsp;advice from a registered professional securities repres=
entative before deciding to trade in stocks featured within this email.&nb=
sp; None of the material within this report shall be construed as any kind=
 of investment advice.<br> <br> In compliance with the Securities Act of 1=
933, Section17(b), Emerging Growth Stock Alert discloses the receipt of $5=
0,000 cash from a third party for the publication of this report and addit=
ional&nbsp;services related to WSCH. Be aware of an inherent conflict of i=
nterest resulting from such compensation.&nbsp; In addition, Emerging Grow=
th Stock Alert intends to receive three million five hundred thousand unre=
stricted shares of WSCH from a third party for the publication of this rep=
ort and additional services related to WSCH.&nbsp; Be aware of an inherent=
 conflict of interest due to our intent to profit from the liquidation of =
these shares. Part or all of this position may be sold at any time, even a=
fter we have made positive statements regarding the above company.&nbsp; A=
ll&nbsp;factual information in this report was gathered from public source=
s, including but not limited to SEC filings, Company Press Releases, and t=
he company's website at wasatchpharm.com.&nbsp;Emerging Growth Stock Alert=
 believes this information to be reliable but can make no guarantee as to =
its accuracy or completeness. Use of the material within this email consti=
tutes your acceptance of these terms.</font><font face=3DVerdana size=3D1>=
<br> &nbsp;</font></td></tr><tr><td vAlign=3Dtop align=3Dleft height=3D36>=
<p align=3Dcenter><b><font face=3DVerdana color=3D#099DF7 size=3D2>To be r=
emoved from future mailings, please reply to this email with &quot;Remove&=
quot; in the subject line</font></b></td></tr></table></td></tr></table></=
td></tr></table></body></html>



